Key result
Treatment of samples with DOAC-Remove successfully reversed DOAC interference in haemostasis assays and prevented inappropriate detection of lupus anticoagulant in 5% of patients.
Why the study?
Despite recommendations, haemostasis testing continues in patients taking direct oral anticoagulants, prompting the evaluation of a diagnostic algorithm using DOAC-Remove to aid accuracy.
Does DOAC-Remove prevent inappropriate detection of lupus anticoagulant and reverse DOAC interference in haemostasis assays for patients taking direct oral anticoagulants?
Observational (n=1,566)
Does DOAC-Remove prevent inappropriate detection of lupus anticoagulant and reverse DOAC interference in haemostasis assays for patients taking direct oral anticoagulants?
Answers are grounded in this paper and cite their sources.
DOAC-Remove effectively eliminates DOAC interference in haemostasis assays, preventing false-positive lupus anticoagulant diagnoses and improving diagnostic accuracy.
) to allow haemostasis assays on patients taking direct oral anticoagulants (DOAC). In the proposed algorithm, patients taking DOAC are screened using the dilute thrombin time (dTT) and anti-Xa assay. If either are positive then DOAC-Remove is utilised. In a validation, DOAC-Remove did not interfere with coagulation testing in normal plasma or in patients on DOAC with a known lupus anticoagulant (LA). Of 1566 routine patient samples tested, 125 (8%) had evidence of anti-Xa activity (>0·1 iu/ml) or prolonged dTT suggestive of either a direct/indirect Xa inhibitor or direct thrombin inhibitor. All of these 125 patients had a prolonged dilute Russell viper venom time (dRVVT) screening test and 106 had a LA detected by dRVVT after phospholipid correction. After DOAC-Remove, 91 patients (73%) had a negative dRVVT screen. After further investigation only 9 (7%) had a positive LA. DOAC-Remove prevented 5% of patients having a LA inappropriately detected. DOAC did not significantly affect the LA activated partial thromboplastin time (aPTT) ratio, protein S antigen or protein C activity. DOAC cause low intrinsic factor assays, high prothrombin time/aPTT and high activated protein C sensitivity ratio, which DOAC-Remove reversed (P < 0·05). Despite recommendations, haemostasis testing for patients on DOAC continues; this algorithm aids diagnostic accuracy. Further validation and research are warranted.
No takes yet. Share an insight, caveat, or question.
Cox‐Morton et al. (2019) conducted an observational in Patients taking direct oral anticoagulants (DOAC) (n=1,566). DOAC-Remove vs. Baseline (pre-DOAC-Remove) was evaluated on Reversal of DOAC interference on intrinsic factor assays, PT/aPTT, and APC sensitivity ratio (p=<0.05). Treatment of samples with DOAC-Remove successfully reversed DOAC interference in haemostasis assays and prevented inappropriate detection of lupus anticoagulant in 5% of patients.
Synapse has enriched 10 related papers. Consider them for comparative context: